

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES.



ABH HEALTHCARE LIMITED

(TO BE LISTED ON EMERGE PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ('NSE EMERGE'))

Our Company was originally incorporated as a private limited company in the name and style of "ABH Healthcare Private Limited" under the Companies Act, 2013 vide certificate of incorporation dated March 2, 2021 issued by Registrar of Companies, Central Registration Centre. Further, in accordance with the main objects, our Company acquired the sole proprietorship concern of Dr. Kamal Baghi, our Promoter in the name "Anil Baghi Hospital" pursuant to a Business Transfer Agreement dated March 16, 2022. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a resolution passed in the Extraordinary general meeting of our members held on October 7, 2024 and consequently, the name of our Company was changed to "ABH Healthcare Limited", and a fresh certificate of incorporation consequent upon conversion dated November 15, 2024 was issued by the Registrar of Companies, Chandigarh.

For details of changes in name and the registered office of the Company, see "History and Certain Corporate Matters – Changes in the Registered Office" on page 154 of the Red Herring Prospectus dated August 13, 2026 ("RHP" or "Red Herring Prospectus").

Registered Office: Anil Baghi Road, Ferozepur, Punjab - 152002, India. **Contact Person:** Mr. Rahul Sharma, Company Secretary & Compliance Officer; **Mob No:** +91 7888690116; **Email:** investor@anilbaghihospital.com; **Website:** www.abhhealthcare.org; **Corporate Identity Number:** U85300PB2021PLC052886

THE PROMOTERS OF OUR COMPANY ARE: DR. KAMAL BAGHI, DR. SAURABH BAGHI AND DR. VAISHALI SAINI

THE ISSUE

INITIAL PUBLIC ISSUE* OF UPTO 34,29,600 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH ("EQUITY SHARES") OF ABH HEALTHCARE LIMITED, ("ABH" OR THE "OUR COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹(+)/- PER EQUITY SHARE (INCLUDING A SECURITIES PREMIUM OF ₹(+/-) PER EQUITY SHARE) (THE "ISSUE PRICE") AGGREGATING TO ₹(+) LAKHS (THE "ISSUE"), OF WHICH 1,72,800* EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹(+)/- PER EQUITY SHARE INCLUDING A SECURITIES PREMIUM OF ₹(+)/- PER EQUITY SHARE AGGREGATING TO ₹(+) LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 32,56,800 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH AT A PRICE OF ₹(+)/- PER EQUITY SHARE INCLUDING A SECURITIES PREMIUM OF ₹(+)/- PER EQUITY SHARE AGGREGATING TO ₹(+) LAKHS IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 30.01% AND 28.49%, RESPECTIVELY, OF THE POST-ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS, PLEASE REFER THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 259 OF THE RHP.

*Subject to finalization of basis of allotment

DETAILS OF THE SELLING SHAREHOLDERS, OFFER FOR SALE AND WEIGHTED AVERAGE COST OF ACQUISITION: *Not applicable as the entire issue constitutes fresh issue of equity shares.*

PRICE BAND: ₹ 96 TO ₹ 102 PER EQUITY SHARE OF FACE VALUE OF ₹ 10/- EACH

FLOOR PRICE IS 9.60 TIMES THE FACE VALUE OF THE EQUITY SHARES AND THE CAP PRICE IS 10.20 TIMES THE FACE VALUE OF THE EQUITY SHARES

THE PRICE TO EARNING RATIO BASED ON DILUTED EPS FOR FY 2026 AT THE FLOOR PRICE IS 13.62 TIMES AND AT THE CAP PRICE IS 14.47 TIMES.

BIDS CAN BE MADE FOR A MINIMUM OF 1,200 EQUITY SHARES AND IN MULTIPLES OF 2,400 EQUITY SHARES THEREAFTER.

WEIGHTED AVERAGE RETURN ON NET WORTH FOR THE LAST THREE FISCALS YEARS SHOULD BE READ AS 44.51%

The details of the Fresh Issue and the Post-Issue Market Capitalisation of the Company, each at the Floor Price (₹ 96) and the Cap Price (₹ 102), are given below

Particulars	At Floor price of ₹ 96 per equity share		At Cap price of ₹ 102 per equity share	
	Upto No. of equity shares of face value of Rs.10/- each	Upto amount (Rs in lakhs)	Upto No. of equity shares of face value of Rs.10/- each	Upto amount (Rs in lakhs)
Fresh Issue	34,29,600	3,292.42	34,29,600	3,498.19
Offer for Sale	-	-	-	-
Total Issue Size	34,29,600	3,292.42	34,29,600	3,498.19
Post-Issue Market Capitalization of the Company	1,14,29,600	10,972.42	1,14,29,600	11,658.19

BID/ISSUE PROGRAMME*

BID/ISSUE OPENS ON: MONDAY AUGUST 24, 2026

BID/ISSUE CLOSES ON: WEDNESDAY AUGUST 26, 2026 ^{(1) (2)}

*Our Company in consultation with the BRLM has decided that no participation by anchor investors will be considered in the IPO.

(1) Our Company, in consultation with the BRLM, may consider closing the Bid/Issue Period for QIBs one Working Day prior to the Bid/Issue Closing Date, in accordance with the SEBI ICDR Regulation.

(2) The UPI mandate end time and date shall be at 5:00 p.m. on the Bid/Issue Closing Day.

BRIEF DESCRIPTION OF THE BUSINESS OF THE COMPANY

Our core focus is on providing specialised tertiary medical care in Tier 3 cities, within the state of Punjab while seeking to strike a balance between providing quality healthcare services and affordability. We operate our hospital under the "Anil Baghi Hospital" brand, honoring the sacrifice of late Shri Anil Baghi. Located in Ferozepur, Punjab, our hospital has a capacity of 150 beds. Acquired by our Company in 2022, the hospital was established in 1985 with 30 (thirty) beds and is driven by a vision to provide affordable, accessible, and quality healthcare services, delivered with compassion. Since our acquisition, we have consistently invested in the hospital, expanding bed capacity, increasing our workforce, and introducing additional services and clinical specialties.

THE ISSUE IS BEING THROUGH BOOK BUILDING PROCESS IN ACCORDANCE WITH CHAPTER IX (INITIAL PUBLIC OFFER BY SMALL AND MEDIUM ENTERPRISES) OF THE SEBI (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED FROM TIME TO TIME ("SEBI ICDR REGULATIONS")

THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON EMERGE PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ('NSE EMERGE')

DETAILS OF ALLOCATION

- QIB CATEGORY: NOT MORE THAN 9.00% OF THE NET ISSUE
- INDIVIDUAL INVESTOR CATEGORY : NOT LESS THAN 45.50% OF THE NET ISSUE
- NON INSTITUTIONAL INVESTOR CATEGORY: NOT LESS THAN 45.50% OF THE NET ISSUE
- MARKET MAKER RESERVATION PORTION: UPTO 1,72,800 EQUITY SHARES OR 5.04% OF THE ISSUE

IN MAKING AN INVESTMENT DECISION, POTENTIAL INVESTORS MUST ONLY RELY ON THE INFORMATION INCLUDED IN THE RHP AND THE TERMS OF THE ISSUE, INCLUDING THE RISKS INVOLVED AND NOT RELY ON ANY OTHER EXTERNAL SOURCES OF INFORMATION ABOUT THE OFFER AVAILABLE IN ANY MANNER

In accordance with the recommendation of the Independent Directors of our Company, pursuant to their resolution dated August 13, 2026 the above provided price band is justified based on quantitative factors/ KPIs disclosed in the Section "Basis for Issue Price" on page 97 of the RHP vis-a-vis the weighted average cost of acquisition ("WACA") of primary and secondary transaction(s), as applicable, disclosed in the section titled "Basis for Issue Price" on page 97 of the RHP and provided below in this advertisement.

RISKS TO INVESTORS

For details refer to section titled "Risk Factors" on page no. 29 of RHP

1. Risk to investors: Summary description of key risk factors based on materiality.

- Our Company has been specifically formed for the purpose of acquisition of the business of M/s. Anil Baghi Hospital (sole proprietorship concern of one of our Promoters), thus we have limited operating history as a Company which may make it difficult for investors to evaluate our historical performance or future prospects.
- Our revenues are significantly dependent on our only hospital in Ferozepur, Punjab, any change in the economic or political circumstances in or around the areas of Ferozepur, could materially affect our business, financial condition and results of operations.
- If we are unable to keep pace with technological changes, new equipments and service introductions, changes in patients' needs and evolving industry standards as well as failure or malfunction of our medical or other equipments, our business and financial condition may be adversely affected.
- We rely on certain third parties, including suppliers, and also enter into contracts with third-party payers such as insurance companies, third party administrators, corporations and government departments. Termination, non-renewal or any breach of the conditions of such contracts could have a material adverse impact on our business, financial condition and results of operations.
- We operate in a highly regulated industry, and compliance with applicable safety, health, environmental and other governmental regulations and any violations of existing regulations may adversely affect our business, results of operations and cash flows.
- Our Company has acquired M/s. Anil Baghi Hospital, the sole proprietorship concern of one of our Promoters after its incorporation vide Business Transfer Agreement dated March 16, 2022. Any future acquisition of other businesses could result in operating difficulties, integration issues and other adverse consequences due to our limited past experience in businesses.
- We are significantly dependent on our key personnel, including our Promoters, Dr. Kamal Baghi, Dr. Saurabh Baghi, Dr. Vaishali Saini, senior management and other healthcare professionals and any loss of or our inability to attract or retain such persons could adversely affect our business, financial condition, results of operations and cash flows.
- The object of making unidentified acquisitions may lead to significant investments in the businesses that may not be sustainable in the long run, which may result in financial losses and negatively impact the company's overall portfolio.
- We do not own the premises where our Registered office and hospital are located. Any adverse event that requires us to vacate the said property may materially adversely affect our business operations and financial conditions
- We have a high debt-equity ratio and may face certain funding risks. Any further increase in borrowings may have a material adverse effect on our business, financial condition and results of operations. Further, if we do not generate sufficient amount of cash flow from operations, our liquidity and ability to service our indebtedness could be adversely affected.

2. Details of suitable ratios of the company for the latest full financial year

Name of the Company	CMP	Face Value (₹)	Revenue from Operations (₹ in Lakhs)	EBITDA	Return On Equity	Return On Capital Employed	EPS (Basic) (₹)	EPS (Diluted) (₹)	P/E*	Return on Net Worth (%)	Net Worth (₹ in Lakhs)	Net Asset Value Per Equity Share (₹)
ABH Healthcare Limited	[*]	10	5,250.69	1,471.65	39.07	19.09	7.05	7.05	[*]	34.26	1,726.54	21.58
Listed Peers*												
Sangani Hospitals Limited	53.20	10	10,695.81	808.63	16.20	20.27	2.17	2.17	24.52	16.20	3,210.65	23.30
Maitreya Medicares Limited	124.15	10	4,484.99	(45.22)	(8.10)	(4.43)	(3.64)	(3.64)	(34.11)	(8.10)	2,891.49	42.67
Asari Hospital Limited	234	10	17,350.29	3,527.76	18.65	16.67	8.47	8.47	27.63	18.65	9,764.41	49.62

- Notes:
- Revenue from Operations means the Revenue from Operations as appearing in the Restated Consolidated Financial Statements.
 - EBITDA is calculated as Restated Profit before tax + Depreciation & amortisation + Interest Expense – Other Income
 - Return on Equity (%) refers to restated profit for the year/period attributable to equity shareholders of our Company divided by Shareholder Equity.
 - Return on Capital Employed is calculated as earnings before interest and taxes divided by Capital Employed.
 - Basic and Diluted EPS = Net Profit (Loss) after tax as restated attributable to Equity Shareholders / weighted average no. of equity shares outstanding during the year (Post effect of bonus) / period as per Restated Financial Statement
 - Return on Net Worth (%) = Net Profit (Loss) after tax as restated attributable to Equity Shareholders / Net worth as restated as at year/period end.
 - P/E Ratio for the peer has been computed based on the closing market price of respective equity shares as on August 13, 2026 sourced from website of Stock Exchange as divided by the Basic/diluted EPS as applicable
 - RoNW is computed as net profit after tax, as attributable to the owners of the Company divided by closing net worth. Net worth has been computed as the aggregate of share capital and reserves and surplus (excluding Revaluation Reserves) and as attributable to the owners of the Company
 - Net worth is aggregate value of the paid-up equity share capital of the Company and all reserves created out of the profits, securities premium account and debit or credit balance of profit and loss account, excluding revaluation reserves if an and share application money, as per Restated Consolidated Financial Statements.
 - Net Asset Value per Equity Share is calculated as net worth attributable to equity shareholders as at the end of Financial period/year divided by the weighted average number of closing outstanding Equity Shares
 - The figures of ABH Healthcare Limited are based on the Restated Consolidated Financial Statements for the Financial year ended March 31, 2026.
 - The figures for the peer group are for the year ended March 31, 2026 and are based on their consolidated financial statements filed with Stock Exchange.

3. Weighted average return on net worth for the last 3 Fys.

Particulars	RoNW (%)	Weights
March 31, 2024	30.33	1
March 31, 2025	59.75	2
March 31, 2026	39.07	3
Weighted Average		44.51

Note: Return on Net worth has been calculated as per the following formula:

- Return on Net Worth (%) = Net Profit (Loss) after tax as restated attributable to Equity Shareholders / Average Net worth as restated as at year/period end.
- Weighted average = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. (RoNW x Weight) for each year/Total of weights.
- Net worth means the aggregate value of the paid-up equity share capital, share premium account, and reserves and surplus (excluding revaluation reserve) as reduced by the aggregate of intangible assets, miscellaneous expenditure (to the extent not adjusted or written off) and the debit balance of the profit and loss account as per Restated Consolidated Financial Statements.
- Weighted average cost of acquisition of all equity shares transacted in the preceding (3) Years, 18 (eighteen) Months and 1 (one) Year preceding the date of the RHP-

Period	Weighted average cost of acquisition** ^	Issue price (₹ [+]) is 'X' times the weighted average cost of acquisition**	Range of acquisition price: Lowest price - Highest price (in ₹)** ^
Last three (3) years	Negligible	N.A.	Nil-33
Last eighteen (18) months	N.A.	N.A.	
Last one (1) year	N.A.	N.A.	N.A.

* As certified by our Statutory Auditor M/s G D Singhal & Associates, Chartered Accountants, pursuant to their certificate dated August 14, 2026

** The face value of Equity Shares is ₹10/- each

6. Disclosures as per clause (9)(K)(4) of Part A to Schedule VI

a) The price per share of our Company (as adjusted for corporate actions, including split, bonus issuances) based on the primary/ new issue of Equity Shares or convertible securities (excluding Equity Shares issued under the ESOP Scheme and issuance of Equity Shares pursuant to a bonus issue) during the 18 months preceding the date of the RHP, where such issuance is equal to or more than 5% of the fully diluted paid up share capital of our Company in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Primary Transactions")

Except bonus issue of Equity Shares, there has been no issuance of Equity Shares or convertible securities, excluding issuance of bonus shares, during the 18 months preceding the date of the RHP, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the Pre-Issue capital before such transaction(s) and excluding ESOPs granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

b) Secondary sales / acquisitions of Equity Shares or any convertible securities, where the Promoters, members of the Promoter Group or Shareholder(s) having the right to nominate director(s) on our Board are a party to the transaction (excluding gifts), during the 18 months preceding the date of the RHP, where either acquisition or sale is equal to or more than 5% of the paid up share capital of our Company (calculated based on the pre-Issue capital before such transaction(s)), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transactions").

There have been no secondary sales / acquisitions of Equity Shares, other than gift or any convertible securities, where the Promoters, members of the Promoter Group or Shareholder(s) having the right to nominate director(s) on our Board are a party to the transaction (excluding gifts), during the 18 months preceding the date of the RHP, where either acquisition or sale is equal to or more than 5% of the paid up share capital of our Company (calculated based on the pre-Issue capital before such transaction(s)), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transactions").

c) Since there are no eligible transaction of our Company reported in 8 (a) and 8 (b) above in accordance with paragraph (9)(K)(4)(a) of the SEBI ICDR Regulations, the price per Equity Share of our Company based on the last five primary or secondary transactions in Equity Shares (secondary transactions where the Promoter/ Promoter Group entities or Shareholders having the right to nominate director on the Board are a party to the transaction) not older than 3 years prior to the date of filing of the RHP has been computed as under:

Date of Transfer	Name of Transferor	Name of Transferee/ Allottee	No. Equity Shares Allotted / Transferred	Face value per Equity Share (₹)	Price per Per Equity Shares (₹)	Nature of transaction	Nature of consideration	Total consideration (in ₹) (B)
Primary Issuances								
April 29, 2025	N.A.	Dr. Saurabh Baghi	41,10,000	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Dr. Kamal Baghi	17,99,988	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Dr. Vaishali Saini	90,000	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Mr. Hem Raj Saini	3	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Mrs. Rita Saini	3	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Mrs. Sukarna Khanna	3	10	NA	Bonus Issue	Other than Cash	N.A.
Total			59,99,997					N.A.
Weighted Average Cost of Acquisition (primary transactions)								
Secondary Issuances								
Date of Transfer	Name of Transferor	Name of Transferee	No. Equity Shares Allotted / Transferred	Face value per Equity Share (₹)	Price per Equity Shares (₹)	Nature of transaction	Total consideration (₹)	
March 31, 2024	Dr. Kamal Baghi	Dr. Saurabh Baghi	13,20,000	10	Nil	Transfer of Equity Shares by way of gift		N.A.
October 1, 2024	Dr. Kamal Baghi	Mr. Hem Raj Saini	1	10	33	Transfer of Equity Shares	33.00	
October 1, 2024	Dr. Kamal Baghi	Mrs. Rita Saini	1	10	33	Transfer of Equity Shares	33.00	
October 1, 2024	Dr. Kamal Baghi	Mrs. Sukarna Khanna	1	10	33	Transfer of Equity Shares	33.00	
Total			13,20,003				99.00	
Weighted Average Cost of Acquisition (secondary transactions)								Negligible

a. Weighted average cost of acquisition and Issue Price

Type of Transactions	Weighted average cost of acquisition (₹ per Equity Shares)	Floor Price (I.e. ₹ 96)	Cap Price (I.e. ₹ 102)
I. Weighted average cost of acquisition for last 18 months for primary / new issue of shares (equity / convertible securities), excluding shares issued under an employee stock option plan / employee stock option scheme and issuance of bonus shares, during the 18 (eighteen) months preceding the date of filing of the RHP, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.	N.A.	N.A.	N.A.
II. Weighted average cost of acquisition for last 18 (eighteen) months for secondary sale/acquisition of shares equity/convertible securities, where promoter/ promoter group entities or shareholder(s) having the right to nominate director(s) in the Board area party to the transaction, during the 18 months preceding the date of filing of the RHP, where either acquisition or sale is equal to or more than five percent of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days	N.A.	N.A.	N.A.
III. Since there are no such transactions to report to under (I) and (II) above, the information has been disclosed for price per share of our Company based on the last five primary or secondary transactions where our Promoter/members of our Promoter Group or Shareholder(s) having the right to nominate director(s) on the Board of our Company, are a party to the transaction, during the three years prior to the date of filing of the RHP irrespective of the size of the transaction, is as below.	N.A.	N.A.	N.A.
Type of transactions	WACA (in ₹)	Floor Price (in ₹)	Cap Price (in ₹)
a) WACA of Equity Shares based on primary issuances undertaken during the three immediately preceding years.	N.A.	N.A.	N.A.
b) WACA of Equity Shares based on secondary transactions undertaken during the three immediately preceding years.	Negligible	N.A.	N.A.

ADDITIONAL INFORMATION FOR INVESTORS:

1. Details of proposed /undertaken pre-issue placements from the DRHP filing date.

Our Company has not undertaken any pre-issue placements or Pre-IPO Placements from the date of the filing of the DRHP till the date of filing of the RHP.

2. Transaction of shares aggregating up to 1% or more of the paid-up equity share capital of the company by promoter(s) and promoter group(s) from the DRHP filing date.- Not Applicable

3. Shareholding of Promoter / Promoter Group and Additional Top 10 Shareholders of the Company

S. No.	Pre-issue shareholding as at the date of Advertisement			Post-issue shareholding as at Allotment			
	Name of Shareholders	Number of Equity Shares ^a	Shareholding(%)	At the Lower end of the Price Band (₹ 96)		At the Upper end of the Price Band (₹ 102)	
				Number of Equity Shares ^a	Shareholding(%)	Number of Equity Shares ^a	Shareholding(%)
Promoters (A)							
1.	Dr. Saurabh Baghi	54,80,000	68.50	54,80,000	47.95%	54,80,000	47.95%
2.	Dr. Kamal Baghi	23,99,984	30.00	23,99,984	21.00%	23,99,984	21.00%
3.	Dr. Vaishali Saini	1,20,000	1.50	1,20,000	1.05%	1,20,000	1.05%
	Total (A)	79,99,984	100.00	79,99,984	69.99%	79,99,984	69.99%
Promoter Group (B)(1)							
1.	Mr. Hem Raj Saini	4	Nominal	4	Nominal	4	Nominal
2.	Mrs. Rita Saini	4	Nominal	4	Nominal	4	Nominal
3.	Mrs. Sukarna Khanna	4	Nominal	4	Nominal	4	Nominal
	Total (B)	12	Nominal	12	Nominal	12	Nominal
Top 10 Shareholders (other than A & B above)							
1.	Mr. Pradeep Khanna ^	4	Nominal	4	Nominal	4	Nominal
	Total (C)	4	Nominal	4	Nominal	4	Nominal
Other Shareholders (other than A, B & C above)							
N.A							
	Total (D)	N.A	N.A	N.A	N.A	N.A	N.A
	Grand Total (A+B+C+D)	80,00,000	100.00	80,00,000	69.99%	80,00,000	69.99%

^ Mr. Pradeep Khanna is the spouse of Mrs. Sukarna Khanna, a member of the Promoter Group.

Notes:

(1) Includes all transfers of Equity Shares by existing shareholders after the date of the pre-issue and price band advertisement. The Promoter Group shareholders are Mr. Hem Raj Saini, Mrs. Rita Saini and Mrs. Sukarna Khanna

(2) Based on the Issue price of ₹(+) and subject to finalization of the basis of allotment.

(3) Assuming full subscription in the Issue. The post-issue shareholding details as at allotment will be based on the actual subscription and the final issue price and updated in the prospectus, subject to finalization of the basis of allotment. Also, this table assumes there is no transfer of shares by these shareholders between the date of the advertisement and allotment (if any such transfers occur prior to the date of prospectus, it will be updated in the shareholding pattern in the prospectus.

Continued on next page...

Continued from previous page

BASIS FOR ISSUE PRICE

The "Basis for Issue Price" on page 96 of the Issue document has been updated with the above price band. Please refer to the website of the BRLM or scan the given QR code for the "Basis for Issue Price" updated with the above price band.

The Price Band will be determined by our Company, in consultation with the BRLM on the basis of the following qualitative and quantitative factors. The face value of the Equity Share is ₹ 10 per Equity Share. The face value of the Equity Shares is ₹ 10 each and the Issue Price is 9.60 times the face value at the lower end of the Price Band and 10.20 times the face value at the higher end of the Price Band.

Investors should refer chapters titled "Risk Factors", "Business Overview", "Restated Consolidated Financial Statements" and "Management Discussion and Analysis of Financial Condition and Results of Operations" on page 28, 124, 177 and 216 respectively of the Red Herring Prospectus to get an informed view before making an investment decision. The trading price of the Equity shares of our Company could decline due to risk factors and you may lose all or part of your investments.

Qualitative Factors

Some of the qualitative factors, which form the basis for computing the price, are:

- a) Doctor-led professional management team with proven execution capabilities;
- b) Delivering quality clinical care by attracting and retaining experienced and renowned clinicians;
- c) Diversified operations across clinical specialties, payor mix and hospitals;
- d) Robust operating infrastructure including information technology and modern equipments; and
- e) Track record of stable operating and financial performance and growth.

For further details, see "Business Overview" on page 124 of the Red Herring Prospectus.

Quantitative Factors

Information presented below relating to the Company is based on the Restated Consolidated Financial Statements for the Fiscal 2026, Fiscal 2025 and Fiscal 2024. Some of the quantitative factors which form the basis or computing the price, are as follows:

1) Basic and Diluted Earnings per Share (EPS)

Particulars	Basic EPS and Diluted EPS	Weights
March 31, 2024	2.07	1
March 31, 2025	6.68	2
March 31, 2026	7.05	3
Weighted Average	6.10	

Note:

- i. The face value of each Equity Share is ₹ 10.
- ii. Basic and diluted Earnings per share calculations are in accordance with Indian GAAP and Accounting Standard as applicable and based on the Restated Consolidated Financial Statement of our Company.
- iii. Basic and Diluted EPS = Net Profit (Loss) after tax as restated attributable to Equity Shareholders / weighted average no. of equity shares outstanding during the year (Post effect of bonus) (period as per Restated Consolidated Financial Statement). Weighted average no. of equity shares are calculated after considering bonus Equity shares issued before date of signing of the Restated Consolidated Financial Statements.
- iv. Weighted Average EPS = Aggregate of Year-wise weighted EPS divided by the Aggregate weights i.e. [EPS * Weights] for each year / Total Weights.
- v. The above statement should be read with significant accounting policies and notes on Restated Consolidated Financial Information as appearing in the Restated Consolidated Financial Statements.
- vi. The above EPS is considered after inclusion of 60,00,000 bonus Equity Shares issued on April 29, 2025
- vii. Price to Earnings (P/E) ratio in relation to Issue Price ₹ [•] per Equity Share of ₹ 10 each fully paid up

Particulars	P/E ratio
P/E ratio based on Basic & Diluted EPS for the Fiscal 2026	[•]
P/E ratio based on Weighted Average	[•]
Industry Peer Group P/E ratio*	
Highest*	27.63
Lowest*	24.52
Average*	26.08

Source: BSE and NSE Website

The figures for the peer group are for the financial year ended March 31, 2026 and are based on their respective standalone and consolidated financial statements, as the case may be filed with Stock Exchanges. CMP of the peer group is as per the closing price as on August 13, 2026 as available on the websites of the Stock Exchanges.

3) Return on Net worth (RoNW)

Return on Net Worth (RoNW) as per Restated Consolidated Financial Statements:

Particulars	RoNW (%)	Weights
March 31, 2024	30.33	1
March 31, 2025	59.75	2
March 31, 2026	39.07	3
Weighted Average	44.51	

Note: Return on Net worth has been calculated as per the following formula:

- i. Return on Net Worth (%) = Net Profit (Loss) after tax as restated attributable to Equity Shareholders / Average Net worth as restated as at year/period end.
- ii. Weighted average = Aggregate of year-wise weighted RoNW divided by the aggregate of weights i.e. (RoNW * Weight) for each year/Total of weights.
- iii. Net worth means the aggregate value of the paid-up equity share capital, share premium account, and reserves and surplus (excluding revaluation reserve) as reduced by the aggregate of intangible assets, miscellaneous expenditure (to the extent not adjusted or written off) and the debit balance of the profit and loss account as per Restated Consolidated Financial Statements.

6) Comparison with industry peers

While our listed peers (mentioned below), like us, operate in the same industry and may have similar offerings, they derive significant portion of revenue. Our business may be different in terms of differing business models.

Particulars	ABH Healthcare Limited			Sangani Hospitals Limited			Maitreya Medicare Limited			Asari Hospital Limited		
	March 31, 2026	March 31, 2025	March 31, 2024	March 31, 2026	March 31, 2025	March 31, 2024	March 31, 2026	March 31, 2025	March 31, 2024	March 31, 2026	March 31, 2025	March 31, 2024
Revenue from operations	5,250.69	4,926.71	4,138.02	10,695.81	2118.52	1,567.62	4,484.99	4,666.20	4,776.30	17,350.29	12,026.57	8,404.04
Growth in Revenue from Operations %	6.58	19.06	39.75	404.87	35.14	0.05	(3.88)	(2.31)	21.29	43.91	42.85	19.37
EBITDA	1,471.65	1,319.51	689.28	808.63	245.06	307.41	(45.22)	486.21	622.88	3,527.76	2,354.79	1,605.09
EBITDA Margin %	28.03	26.78	16.66	7.56	11.57	19.61	(1.01)	10.46	13.04	20.33	19.53	19.02
PAT	563.94	534.70	165.56	552.51	259.38	269.69	(246.53)	187.24	317.12	1,666.09	1,057.61	416.16
PAT Margin %	10.74	10.85	4.00	5.17	12.24	17.20	(5.50)	4.01	6.64	9.60	8.77	4.93
Net Worth	1,726.54	1,160.22	629.53	3,210.65	3,608.57	3,349.19	2,891.49	3,193.86	3,022.61	9,764.41	8,098.32	7,040.70
Capital Employed	7,430.49	5,488.98	4,284.64	3,409.61	3,617.10	3,357.72	5,203.31	3,714.78	3,592.86	15,520.14	12,954.05	10,231.92
RoE %	39.07	59.75	30.33	16.20	7.46	10.48	(8.10)	6.02	14.23	18.65	13.97	7.41
RoCE %	19.09	22.70	14.96	20.27	5.32	10.80	(4.43)	9.41	17.66	16.67	9.38	9.00
Debt - Equity Ratio	3.20	3.62	5.69	0.06	0.00	0.00	0.80	0.16	0.19	0.59	0.60	0.45
Fixed Assets Turnover Ratio	1.25	1.35	1.23	3.36	1.61	1.24	1.10	3.06	3.34	1.60	1.19	0.90
Net Cash from/(used in) Operating Activities	211.07	354.42	88.81	500.49	234.58	336.91	844.84	505.68	(215.39)	1,830.43	(434.98)	2,607.41

Notes:

- i. Financial and Non-GAAP information are based on consolidated audited financial statements, unless specified of peer companies filed with the Stock Exchanges and the information available on website

Comparison of Accounting Ratios with Listed Industry Peers

Set forth below are the details of comparison of key performance indicators with our listed industry peers:

Name of the company	Consolidated/ Standalone	Current Market Price (CMP)	Revenue from Operations (₹ in Lakhs)	EPS (in ₹)		P/E Ratio	PAT margin (%)	RONW (%)	NAV (Per Share)	Face Value (in ₹)	Market cap to Revenue from operation
				Basic	Diluted						
ABH Healthcare Limited	Consolidated	[•]	5,250.69	7.05	7.05	[•]	10.74	34.25	21.58	10.00	[•]
Peer Group											
Sangani Hospitals Limited	Consolidated	53.20	10,695.81	2.17	2.17	24.52	5.17	16.20	23.30	10.00	0.69
Maitreya Medicare Limited	Consolidated	124.15	4,484.99	(3.64)	(3.64)	(34.11)	(5.50)	(8.10)	42.67	10.00	1.88
Asari Hospital Limited	Consolidated	234	17,350.29	8.47	8.47	27.63	9.60	18.65	49.62	10.00	2.65

Source: All the financial information for listed industry peers mentioned above is on a consolidated basis and is sourced from the annual reports/ financial results as available of the respective company for the financial year ended March 31, 2026 submitted to stock exchanges or on company's website as available on www.bseindia.com and www.nseindia.com

Notes:

- a) The figures ABH Healthcare Limited are based on the Restated Consolidated Financial Statements for the Fiscal 2026.
- b) Current market price (CMP) is the closing market price of the equity shares of the respective companies on NSE on August 13, 2026.
- c) Diluted EPS refers to the diluted earnings per share sourced from the annual reports/annual results as available of the respective company for the year ended March 31, 2026 submitted to stock exchanges
- d) NAV is computed as the closing net worth divided by the closing outstanding number of equity shares. Net worth means the aggregate value of the paid-up equity share capital, share premium account, and reserves and surplus (excluding revaluation reserve) as reduced by the aggregate of intangible assets, miscellaneous expenditure (to the extent not adjusted or written off) and the debit balance of the profit and loss account.
- e) P/E Ratio for the peer has been computed based on the closing market price of respective equity shares as on August 13, 2026 sourced from website of Stock Exchange as divided by the Basic/Diluted EPS as applicable.
- f) RoNW is computed as net profit after tax, as attributable to the owners of the Company divided by closing net worth. Net worth means the aggregate value of the paid-up equity share capital, share premium account, and reserves and surplus (excluding revaluation reserve) as reduced by the aggregate of intangible assets, miscellaneous expenditure (to the extent not adjusted or written off) and the debit balance of the profit and loss account.
- 7) Weighted average cost of acquisition
- a. The price per share of our Company (as adjusted for corporate actions, including split, bonus issuances) based on the primary/ new issue of Equity Shares or convertible securities (excluding Equity Shares issued under the ESOP Scheme and issuance of Equity Shares pursuant to a bonus issue) during the 18 months preceding the date of the Red Herring Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid up share capital of our Company in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Primary Transactions")
- Except bonus issue of Equity Shares, there has been no issuance of Equity Shares or convertible securities, including issuance of bonus shares, during the 18 months preceding the date of Red Herring Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the Pre-issue capital before such transaction(s) and excluding ESOPs granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.
- b. Secondary sales / acquisitions of Equity Shares or any convertible securities, where the Promoters, members of the Promoter Group or Shareholder(s) having the right to nominate director(s) on our Board are a party to the transaction (excluding gifts), during the 18 months preceding the date of the Red Herring Prospectus, where either acquisition or sale is equal to or more than 5% of the paid up share capital of our Company (calculated based on the pre-issue capital before such transaction(s)), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transactions").
- There have been no secondary sales / acquisitions of Equity Shares, other than gift or any convertible securities, where the Promoters, members of the Promoter Group or Shareholder(s) having the right to nominate director(s) on our Board are a party to the transaction (excluding gifts), during the 18 months preceding the date of the Red Herring Prospectus, where either acquisition or sale is equal to or more than 5% of the paid up share capital of our Company (calculated based on the pre-issue capital before such transaction(s)), in a single transaction or multiple transactions combined together over a span of rolling 30 days ("Secondary Transactions").
- c. Since there are no eligible transaction of our Company reported in 8 (a) and 8 (b) above in accordance with paragraph (9)(K)(4)(a) of the SEBI ICDR Regulations, the price per Equity Share of our Company based on the last five primary or secondary transactions where the Promoter/ Promoter Group entities or Shareholders having the right to nominate director on the Board are a party to the transaction) not older than 3 years prior to the date of filing of the Red Herring Prospectus has been computed as under:

Date of Transfer	Name of Transferor	Name of Transferee/ Allottee	No. Equity Shares Allotted / Transferred	Face value per Equity Share (₹)	Price per Per Equity Shares (₹)	Nature of transaction	Nature of consideration	Total consideration (in ₹) (B)
Primary Issuances								
April 29, 2025	N.A.	Dr. Saurabh Baghi	41,10,000	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Dr. Kamal Baghi	17,99,988	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Dr. Valsahi Saini	90,000	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Mr. Hem Raj Saini	3	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Mrs. Rita Saini	3	10	NA	Bonus Issue	Other than Cash	N.A.
April 29, 2025	N.A.	Mrs. Sukarma Khanna	3	10	NA	Bonus Issue	Other than Cash	N.A.
Total			59,99,997					N.A.

Weighted Average Cost of Acquisition (primary transactions)

Secondary Issuances								
Date of Transfer	Name of Transferor	Name of Transferee	No. Equity Shares Allotted / Transferred	Face value per Equity Share (₹)	Price per Equity Shares (₹)	Nature of transaction	Nature of consideration	Total consideration (₹)
March 31, 2024	Dr. Kamal Baghi	Dr. Saurabh Baghi	13,20,000	10	Nil	Transfer of Equity Shares by way of gift		N.A.
October 1, 2024	Dr. Kamal Baghi	Mr. Hem Raj Saini	1	10	33	Transfer of Equity Shares		33.00
October 1, 2024	Dr. Kamal Baghi	Mrs. Rita Saini	1	10	33	Transfer of Equity Shares		33.00
October 1, 2024	Dr. Kamal Baghi	Mrs. Sukarma Khanna	1	10	33	Transfer of Equity Shares		33.00
Total			13,20,003					99.00

Weighted Average Cost of Acquisition (secondary transactions)

d) Weighted average cost of acquisition and Issue Price

Type of Transactions	Weighted average cost of acquisition (₹ per Equity Shares)	Floor Price (i.e. ₹ 96)	Cap Price (i.e. ₹ 102)
	N.A.	N.A.	N.A.

i. Weighted average cost of acquisition for last 18 months for primary / new issue of shares (equity / convertible securities), excluding shares issued under an employee stock option plan / employee stock option scheme and issuance of bonus shares, during the 18 (eighteen) months preceding the date of filing of the Red Herring Prospectus, where such issuance is equal to or more than 5% of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

4) Net Asset Value (NAV)

Particulars	(₹)
Net Asset Value per Equity Share as of March 31, 2026	21.58
Net Asset Value per Equity Share as of March 31, 2025	14.50
Net Asset Value per Equity Share after IPO	[•]
Issue Price per Equity Share	[•]

Notes:

- i) Net Asset Value per Equity Share is calculated as net worth attributable to equity shareholders as at the end of Financial period/year divided by the weighted average number of Equity Shares used in calculating basic earnings per share after considering bonus Equity Shares.

"Net worth means the aggregate value of the paid-up equity share capital, share premium account, and reserves and surplus (excluding revaluation reserve) as reduced by the aggregate of intangible assets, miscellaneous expenditure (to the extent not adjusted or written off) and the debit balance of the profit and loss account, if any"

- ii) To be decided upon finalization of Issue Price per Equity Share.

5) Key Performance Indicators

The table below sets forth the details of that our Company considers have a bearing for arriving at the basis for Issue Price. The key financial and operational metrics set forth above, have been approved and verified by the members of the Audit Committee pursuant to their resolution dated August 13, 2025. Further, the Audit Committee has on August 13, 2026 taken on record that other than the key financial and operational metrics set out below, our Company has not disclosed any other KPIs during the three years preceding the date of the Red Herring Prospectus with its investors. The KPIs disclosed below have been used historically by our Company to understand and analyze the business performance, which in result, help it in analyzing the growth of various verticals in comparison to our Company's peers, and other relevant and material KPIs of the business of our Company that have a bearing for arriving at the Basis for Issue Price have been disclosed below. Additionally, the KPIs have been certified by our Statutory Auditors - M/s. G D Singhal & Associates, Chartered Accountants, vide their certificate August 13, 2026 and has been included in "Material Contracts and Documents for Inspection" on page 326 of the Red Herring Prospectus.

The KPIs disclosed below have been used historically by our Company to understand and analyze the business performance, which in result, help us in analyzing the growth of our Company.

The KPIs of our Company have been disclosed in the chapters titled "Business Overview" and "Management's Discussion and Analysis of Financial Condition and Results of Operations - Key Performance Indicators" on pages 124 and 216 respectively of the Red Herring Prospectus. We have described and defined the KPIs, as applicable, in "Definitions and Abbreviations" on page 2 of the Red Herring Prospectus.

Comparison of KPIs based on material additions or dispositions to our business

Our Company has not made any additions or dispositions to our business in the last three Fiscals except the following additions:

- a. Anil Baghi Hospital (sole proprietorship concern of Dr. Kamal Baghi)
- b. Five Creeks Healthcare LLP (LLP with 90% capital interest)
- c. ABH Clinics LLP (LLP with 90% capital interest)

Our Company has not undertaken material acquisition or disposition of assets / business for the periods that are covered by the KPIs and accordingly, no comparison of KPIs over time based on additions or dispositions to the business, have been provided.

Our Company confirms that it shall continue to disclose all the KPIs included in this chapter on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or for such other duration as may be required under the SEBI ICDR Regulations. Further, the ongoing KPIs will continue to be certified by a member of an expert body as required under the SEBI ICDR Regulations.

Key Performance Indicators of our Company based on the Restated Consolidated Financial Statements.

Particulars	Fiscal 2026	Fiscal 2025	Fiscal 2024
Revenue from Operations * (₹ in Lakhs)	5,250.69	4,926.71	4,138.02
Growth in Revenue from Operations (%) ⁽ⁱ⁾	6.58	19.06	39.75
EBITDA (₹ in Lakhs) ⁽ⁱⁱ⁾	1,471.65	1,319.51	689.28
EBITDA Margin (%) ⁽ⁱⁱⁱ⁾	28.03	26.78	16.66
Restated Profit After Tax (₹ in Lakhs)	563.94	534.70	165.56
PAT Margin (%) ^(iv)	10.74	10.85	4.00
Net Worth ^(v) (₹ in Lakhs)	1,726.54	1,160.22	629.53
Capital Employed (₹ in Lakhs)	7,430.49	5,488.98	4,284.64
RoE (%) ^(vi)	39.07	59.75	30.33
RoCE (%) ^(vii)	19.09	22.70	14.96
Debt - Equity Ratio ^(viii)	3.20	3.62	5.69
Fixed Assets Turnover Ratio ^(ix)	1.25	1.35	1.23

Notes:

- (1) Revenue from Operations means the Revenue from Operations as appearing in the Restated Consolidated Financial Statements.
- (2) Growth in Revenue from Operations (%) is calculated as Revenue from Operations of the relevant period minus Revenue from Operations of the preceding period, divided by Revenue from Operations of the preceding period.
- (3) EBITDA is calculated as Profit before tax + Depreciation & amortisation + Finance Cost (incl. bank charges) - Other Income
- (4) EBITDA Margin (%) is calculated as EBITDA divided by Revenue from Operations
- (5) PAT Margin (%) is calculated as PAT for the period/year divided by Revenue from operations.
- (6) Net worth means the aggregate value of the paid-up equity share capital, share premium account, and reserves and surplus (excluding revaluation reserve) as reduced by the aggregate of intangible assets, miscellaneous expenditure (to the extent not adjusted or written off) and the debit balance of the profit and loss account.

- (7) Return on Equity (%) refers to restated profit for the year/period attributable to equity shareholders of our Company divided by Average Net Worth.

- (8) Return on Capital Employed is calculated as earnings before interest and taxes divided by Average Capital Employed. Capital Employed is calculated as total equity plus total debt and deferred tax liabilities minus intangible assets and deferred tax assets.

- (9) Debt Equity Ratio: This is defined as total debt divided by total equity. Total debt is the sum of total current & non-current borrowings including interest accrued but not due; total equity means Net Worth i.e. the aggregate value of the paid-up equity share capital, share premium account, and reserves and surplus (excluding revaluation reserve) as reduced by the aggregate of intangible assets, miscellaneous expenditure (to the extent not adjusted or written off) and the debit balance of the profit and loss account.

- (10) Fixed Asset Turnover Ratio: This is defined as revenue from operations divided by total of net book property, plant & equipment. Figures for property, plant & equipment do not include capital work-in-progress and intangible assets.

-Earnings before interest and tax is calculated as restated profit / (loss) for the period / year plus total tax expense / (credit) plus finance costs reduced by other income.

Explanation of KPI Metrics:

KPI	Explanations
Revenue from Operations	Revenue from Operations is used by our management to track the revenue profile of the business and in turn helps to assess the overall financial performance of our Company and volume of our business
Growth in Revenue from Operations	Growth in Revenue from Operations provides information regarding the growth of our business for respective periods
EBITDA	EBITDA provides information regarding the operational efficiency of the business
EBITDA Margin (%)	EBITDA Margin (%) is an indicator of the operational profitability and financial performance of our business
Restated Profit After Tax	Profit after tax provides information regarding the overall profitability of the business.
PAT Margin (%)	PAT Margin (%) is an indicator of the overall profitability and financial performance of our business
Net Worth	Net worth is used by the management to ascertain the total value created by the entity and provides a snapshot of current financial position of the entity.
Capital Employed	Capital employed is to measure how effectively a company utilizes its overall resources to generate profits
RoE (%)	RoE provides how efficiently our Company generates profits from shareholders' funds.
RoCE%	ROCE provides how efficiently our Company generates earnings from the capital employed in the business.
Debt Equity Ratio	This gearing ratio compares shareholders' equity to company debt to assess the company's amount of leverage and financial stability.
Fixed Assets Turnover Ratio	This ratio is a financial metric that measures how effectively a company utilizes its long term assets to generate revenue.

Operational KPIs of the Company on standalone basis

Particulars	Fiscal 2026	Fiscal 2025	Fiscal 2024
Total Bed Capacity ⁽ⁱ⁾	150	150	100
Approved Beds ⁽ⁱⁱ⁾	150	150	100
Operational Beds ⁽ⁱⁱⁱ⁾	125	125	85
ICU Beds	70	70	49
IPD Volume	6,387	6,339	5,723
IPD Revenue (₹ in Lakhs)	4,290.65	4,090.44	3,476.03
OPD Volume	53,212	53,556	43,415</

.....Continued from previous page

Modification/ Revision/cancellation of Bids	
Upward Revision of Bids by Individual Investors, QIBs and Non-Institutional Investors categories	Only between 10.00 a.m. on the Bid/Issue Opening Date and up to 4.00 p.m. IST on Bid/Issue Closing Date
*UPI mandate end time and date shall be at 5:00 pm on the Bid/Issue Closing Date	
* Individual Investors, QIBs and Non-Institutional Investors can neither revise their bids downwards nor cancel/ withdraw their Bids. On the Bid/Issue Closing Date, the Bids shall be uploaded until: (i) 4.00 p.m. IST in case of Bids by Individual Investors QIBs and Non-Institutional Investors.	
Event	Indicative Dates
BID/ISSUE OPENING DATE	Monday, August 24, 2026
BID/ISSUE CLOSING DATE	Wednesday, August 26, 2026
FINALIZATION OF BASIS OF ALLOTMENT WITH THE DESIGNATED STOCK EXCHANGE (T + 1)	Thursday, August 27, 2026
INITIATION OF ALLOTMENT / REFUNDS / UNBLOCKING OF FUNDS FROM ASBA ACCOUNT OR UPI ID LINKED BANK ACCOUNT (T + 2)	Friday, August 28, 2026
CREDIT OF EQUITY SHARES TO DEMAT ACCOUNTS OF ALLOTTEES (T + 2)	Friday, August 28, 2026
COMMENCEMENT OF TRADING OF THE EQUITY SHARES ON THE STOCK EXCHANGE (T + 3)	Monday, August 31, 2026

ASBA*	Simple, Safe, Smart way of Application-Make use of it!!!!	*Applications Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For details check section on ASBA below.	Mandatory in Public Issues from January 01, 2016. No cheque will be accepted
--------------	---	--	--

UPI - Now available in ASBA for Individual Investors and Non-Institutional Investor applying for amount up to ₹ 5,00,000/- applying through Registered Brokers, DPs & RTAs. UPI Bidder also have the option to submit the Application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the Bank Account used for bidding is linked to their PAN. Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CBOIT notification dated February 13, 2020, issued by the CBOIT and the subsequent press release, including press release dated June 25, 2021 and September 17, 2021 and CBOIT circular no. 7 of 2022, dated March 30, 2022 read with press release dated March 28, 2023 and any subsequent press releases in this regard.

ASBA has to be availed by all the investors. UPI may be availed by (i) Individual Investors in the Individual Investors Portion and ii) Non-Institutional Investors with an application size of up to ₹ 5,00,000 in the Non-Institutional Portion. For details on the ASBA and UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section "Issue Procedure" on page 272 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIBI") and Stock Exchanges and in the General Information Document. ASBA bid-cum-application forms can be downloaded from the website of Stock Exchange and can be obtained from the list of banks that is displayed on the website of SEBI at <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?do=RecognisedFpi=yes&intmid=36> and <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?do=RecognisedFpi=yes&intmid=43>, respectively as updated from time to time. For the list of UPI apps and banks live on IPO, please refer to the link: www.sebi.gov.in. UPI mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, as updated from time to time. Kotak Mahindra Bank Limited has been appointed as Sponsor Bank for the Issue, in accordance with the requirements of the SEBI Circular dated November 1, 2016 as amended. For issue related queries, please contact the BRLM on their email ID as mentioned below. For UPI related queries, investors can contact NPCI at the toll-free number: 18001201740 and mail ID: ipo.upi@npci.org.in.

In case of any revision in the Price Band, the Bid/Issue Period will be extended by at least three additional Working Days after such revision of the Price Band, subject to the Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing, extend the Bid/Issue Period by a minimum of one Working Day, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Issue Period, if applicable, will be widely disseminated by notification to the Stock Exchange, by issuing a press release, and also by indicating the change on the website of the Book Running Lead Manager and the terminals of the other members of the Syndicate and by intimation to SCSBs, the Sponsor Bank, Registered Brokers, Collecting Depository Participants and Registrar and Share Transfer Agents.

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended the "SCRR" read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253(1) and 253(2) of the SEBI ICDR Regulations read with SEBI ICDR (Amendment) Regulations, 2025, wherein not more than 9.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further not less than 45.50% of the Net Issue shall be available for allocation to Individual Investors who applies for minimum application size. Not less than 45.50% of the Net Issue shall be available for allocation to Non-Institutional Investors of which one-third of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than two lots and up to such lots as equivalent to not more than ₹10.00 Lakhs and two-thirds of the Non-institutional Portion will be available for allocation to Bidders with an application size of more than ₹10.00 Lakhs and under-subscription in either of these two sub-categories of Non Institutional Portion may be allocated to Bidders in the other sub-category of Non- Institutional Portion. Subject to the availability of shares in non-institutional investors' category, the allotment to each Non- institutional Investors shall not be less than the minimum application size in Non-institutional Category and the remaining available Equity Shares, if any, shall be allocated on a proportionate basis in accordance with the conditions specified in this regard in Schedule XII of the SEBI (ICDR) Regulations, 2025. All Potential Bidders, are required to participate in the Issue by mandatorily utilising the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Sett-Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Issue Procedure" on page 272 of the RHP.

Bidders/Applicants should note that on the basis of PAN, DP ID and Client ID as provided in the Bid cum Application Form, the Bidders/Applicants may be deemed to have authorized the Depositories to provide to the Registrar to the Issue, any requested Demographic Details of the Bidders/Applicants as available on the records of the depositories. These Demographic Details may be used, among other things, for or unblocking of ASBA Account or for other correspondence(s) related to an Issue. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Applicants' sale risk. Bidders/Applicants should ensure that PAN, DP ID and the Client ID are correctly filled in the Bid cum Application Form. The PAN, DP ID and Client ID provided in the Bid cum Application Form should match with the PAN, DP ID and Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Investors must ensure that their PAN is linked with AADHAAR and are in compliance with CBOIT Notification dated February 13, 2020 and press release dated June 25, 2021.

CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AS REGARDS ITS OBJECTS: For information on the main objects and other objects of our Company, see "History and Corporate Structure" on page 154 of the RHP and Clause III of the Memorandum of Association of our Company. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section "Material Contracts and Documents for Inspection" on page 326 of the RHP.

LIABILITY OF MEMBERS AS PER MOA: Limited by shares.

AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: As on the date of RHP, the Authorized share Capital of the Company is ₹13,00,00,000 divided into 1,30,00,000 Equity Shares of face value ₹s.10 each. The Issued subscribed and paid-up share capital before the Issue is ₹ 8,00,00,000 divided into 80,00,000 Equity Shares of face value ₹s.10 each. For details of the Capital Structure, see "Capital Structure" on the page 76 of the RHP.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM:

Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed for by them at the time of signing of the Memorandum of Association of our Company: Dr. Saurabh Baghi (40,000 Equity shares), Dr. Vaishali Saini (30,000 Equity shares) Late Dr. Mukta Baghi (30,000 Equity shares) of face value ₹s.10 each.

LISTING: The Equity Shares offered through the RHP are proposed to be listed on the Emerge platform of National Stock Exchange of India Limited ("NSE EMERGE"). Our Company has received an "in-principle" approval from the National Stock Exchange of India Limited for the listing of the Equity Shares pursuant to letter dated December 01, 2025. For the purposes of the Issue, the Designated Stock Exchange shall be National Stock Exchange of India Limited. A signed copy of the RHP has been submitted for registration to the ROC on August 14, 2026 and Prospectus shall be filed with the RoC in accordance with Section 26(4) of the Companies Act, 2013.

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA ("SEBI"): Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018. The RHP has been filed with SEBI, the SEBI shall not issue any observation on the Offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire "Disclaimer Clause of SEBI" on page 250 of the RHP.

DISCLAIMER CLAUSE OF EMERGE PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE EMERGE") (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to the Offer Document for the full text of the "Disclaimer Clause of NSE".

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the RHP. Specific attention of the investors is invited to "Risk Factors" on page 29 of the RHP.

TRACK RECORD OF BOOK RUNNING LEAD MANAGER: The BRLM has handled 3 Main Board Issues till date and 29 SME Issues in the past three fiscals, out of which 1 Main Board and 3 SME Issues closed below the Issue Price on the listing date.

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 FEDEX SECURITIES PRIVATE LIMITED B 7, 3 rd Floor, Jay Chambers, Dayaldas Road, Vile Parle (East), Mumbai - 400 057, Maharashtra, India Telephone + 91 81049 85249; E-mail: mb@fedsec.in Investor Grievance E-Mail: investors@fedsec.in Website: www.fedsec.in Contact Person: Ms. Karuna Bangera/ Mr. Saipal Sanghi SEBI Registration Number: INM000010163	 BIGSHARE SERVICES PRIVATE LIMITED 56-2, 6 th Floor, Pinnacle Business Park, Mahakali Caves Road, next to Ahura Centre, Andheri East, Mumbai- 400093, Maharashtra, India Tel No. + 91 22 66338200 Fax No: N.A. E-mail id: ipo@bigshareonline.com Website: www.bigshareonline.com Investor Grievance Id: investor@bigshareonline.com Contact Person: Mr. Sagar Pathare SEBI Registration No: INR000001385	Mr. Rahul Sharma Anil Baghi Road, Ferozepur, Punjab - 152002, India. Tel No. / Mob No: +91 78886990116 Email: cs@anilbaghihospital.com Website: www.abhhealthcare.org CIN: U85300PB2021PLC052886 Investors may contact the Company Secretary and Compliance Officer or the Registrar to the Issue in case of any pre-issue or post-issue related grievances including non-receipt of letters of allotment, non-credit of allotted equity shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode, etc. For all issue related queries and for redressal of complaints, investors may also write to the BRLM.

AVAILABILITY OF RED HERRING PROSPECTUS: Investors are advised to refer to the RHP and the Risk Factors contained therein before applying in the Issue. Full copy of the RHP is available on the website of SEBI at www.sebi.gov.in, website of the Company at www.abhhealthcare.org, the website of the BRLM to the Issue at www.fedsec.in, the website of NSE at www.nseindia.com respectively.

AVAILABILITY OF THE ABRIDGED PROSPECTUS: A copy of the abridged prospectus shall be available on the website of the Company, BRLM and National Stock Exchange of India at www.abhhealthcare.org, www.fedsec.in and www.nseindia.com respectively.

SYNDICATE MEMBER: Rikhav Securities Limited

AVAILABILITY OF BID-CUM-APPLICATION FORMS: Bid-Cum-Application forms can be obtained from the Registered Office of the Company: ABH Healthcare Limited, Telephone: +91 78886990018; BRLM: Fedex Securities Private Limited, Telephone: +91 81049 85249 and the Syndicate Member: Rikhav Securities Limited, Telephone: 022-69078200 / 300 and at the selected locations of the Sub-Syndicate Members, Registered Brokers, RTAs and CDPs participating in the Issue. Bid-cum-Application Forms will also be available on the websites of NSE and the designated branches of SCSBs, the list of which is available at websites of the Stock Exchange and SEBI.

BANKER TO THE ISSUE/ESCROW COLLECTION BANK/ REFUND BANK/ PUBLIC ISSUE ACCOUNT BANK/ SPONSOR BANK: KOTAK MAHINDRA BANK LIMITED.

UPI: UPI Bidders can also Bid through UPI Mechanism.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

Date August 14, 2026
Place: Ferozepur

Disclaimer- ABH Healthcare Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and the RHP dated August 13, 2026 has been filed with the Registrar of Companies, Chandigarh and thereafter with SEBI and the Stock Exchange. The RHP is available on the website of the SEBI at www.sebi.gov.in, website of NSE at www.nseindia.com and is available on the website of the BRLM at www.fedsec.in. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the RHP including the section titled "Risk Factors" on page 29 of the RHP.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

ਪੁਲਸ ਅਦਾਰੇ 'ਤੇ ਹਮਲੇ ਦੀ ਸਾਜ਼ਿਸ਼ ਨਾਕਾਮ; ਆਈ ਈ ਡੀ ਬਰਾਮਦ

ਫੋਰਟ/ਪਾਸ, (ਮਨੋਜ ਕੁਮਾਰ/ਸ਼ਬਾਨਾ ਸਿੰਘ) : ਅੰਮ੍ਰਿਤਸਰ ਦਿਹਾਤੀ ਪੁਲਸ ਨੇ ਸ਼ਨਿਚਰਵਾਰ ਤੇ ਐਤਵਾਰ ਦੀ ਦਰਮਿਆਨੀ ਰਾਤ ਨੂੰ ਮੇਮ ਨਾਲ ਲਪੇਟੇ ਹੋਏ ਇਕ ਪੇਕਟ, ਜਿਸ ਵਿਚ 690 ਗ੍ਰਾਮ ਵਜ਼ਨ ਵਾਲਾ ਇਕ ਇੰਫੋਵਾਈਰਡ ਐਕਸਪਲੋਸਿਵ ਰਿਫਾਈਲ (ਆਈਐਚਐਚ) ਦੇ ਨਾਲ-ਨਾਲ, ਇਕ ਇਲੈਕਟਰਾਨਿਕ ਡੈਟੇਨੇਟਰ, ਬੈਟਰੀ, ਟਾਈਮਰ ਤੇ ਲੱਭੇ ਹੋਏ ਬਾਕਸ ਸੀ, ਜੋ ਕਰਾਮਦਗੀ ਨਾਲ ਪੁਲਸ ਅਦਾਰੇ ਨੂੰ ਨਿਸ਼ਾਨਾ ਬਣਾਉਣ ਦੀ ਐਤਵਾਰੀ ਸਾਜ਼ਿਸ਼ ਨੂੰ ਨਾਕਾਮ ਕਰ ਦਿੱਤਾ ਹੈ।



ਤੀਸੀਪੀ ਪੰਜਾਬ ਗੋਰਵ ਯਾਵਾ ਨੇ ਦੱਸਿਆ ਕਿ ਜ਼ਬਰ ਕਰਨ ਤੋਂ ਬਾਅਦ ਇਸ ਵਿਸ਼ੇਸ਼ ਸਮੱਗਰੀ ਨੂੰ ਸੁਰੱਖਿਅ ਪ੍ਰੋਟੋਕੋਲ ਅਨੁਸਾਰ ਸੋਧਾਇਆ ਗਿਆ ਤੇ ਥੋਥ ਡਿਸਪੋਜ਼ਲ ਸਕ੍ਰਾਓਡ ਵੱਲੋਂ ਨਸ਼ਾ ਕਰ ਦਿੱਤਾ ਗਿਆ। ਉਨ੍ਹਾਂ ਦੱਸਿਆ ਕਿ ਅੰਮ੍ਰਿਤਸਰ ਦਿਹਾਤੀ ਪੁਲਸ ਨੇ ਦੇਸ਼ ਵਿਰੋਧੀ ਅਨੁਸਾਰ ਦੇ ਮਨੁੱਖ ਨੂੰ ਨਾਕਾਮ ਕਰ ਦਿੱਤਾ ਹੈ ਤੇ ਜਨਤਕ ਸੁਰੱਖਿਆ ਲਈ ਸੰਭਾਵੀ ਖਤਰੇ ਨੂੰ ਟਾਲ ਦਿੱਤਾ ਹੈ।

ਤੀਸੀਪੀ ਨੇ ਦੱਸਿਆ ਕਿ ਇਸ ਸਾਜ਼ਿਸ਼ ਨੂੰ ਘੜਨ ਵਾਲੇ ਫੌਜੀ ਦੀ ਪਛਾਣ ਕਰਨ ਤੇ ਉਨ੍ਹਾਂ ਨੂੰ ਕਾਬੂ ਕਰਨ ਲਈ ਹੋਰ ਸਾਰੇ ਹੀ। ਇਸ ਆਪਰੇਸ਼ਨ ਬਾਰੇ ਜਾਣਕਾਰੀ ਦਿੰਦਿਆਂ ਸੀਨੀਅਰ ਸੁਪਰਡੈਂਟ ਆਫ ਪੁਲਸ

(ਐੱਸਐਸਪੀ) ਅੰਮ੍ਰਿਤਸਰ ਦਿਹਾਤੀ ਕੰਬਲਪ੍ਰੀਤ ਸਿੰਘ ਚਾਹਲ ਨੇ ਕਿਹਾ ਕਿ ਆਜ਼ਾਦੀ ਦਿਹਾਤੇ ਦੇ ਮੌਦੇਨਸਰ ਚੌਕਿਸ਼ ਪੁਆਇੰਟ 'ਤੇ ਪਹਿਲਾਂ ਹੀ ਜਾਂਚ ਤੋੜ ਕਰ ਦਿੱਤੀ ਗਈ ਸੀ ਤੇ ਸਰਕਾਰੀ ਅਦਾਰਿਆਂ 'ਤੇ ਵੀ ਨੌਟਿਫਿ ਨਸਰ ਰੱਖੀ ਜਾ ਰਹੀ ਸੀ। ਉਨ੍ਹਾਂ ਦੱਸਿਆ ਕਿ ਇਸ ਸਬੰਧੀ, 15-16 ਅਗਸਤ, 2026 ਦੀ ਰਾਤ ਨੂੰ ਜਦੋਂ ਐੱਸਐਸਪੀ ਕੁਲਬੀਰ ਸਿੰਘ ਰਾਏ ਸਮੇਂ ਗਸ਼ਤ ਕਰ ਰਹੇ ਸਨ ਤਾਂ ਪੁਲਸ ਚੌਕੀ ਗੰਗਿਆਲ ਦੇ ਅਧਿਕਾਰ ਖੇਤਰ ਵਿਚ ਬੰਕੀ ਕਲਾਂ ਰੋਡ 'ਤੇ ਆਮ ਨਾਲ ਲਪੇਟਿਆ ਪੇਕਟ ਮਿਲਿਆ। ਉਨ੍ਹਾਂ ਦੱਸਿਆ ਕਿ ਜਾਂਚ ਕਰਨ 'ਤੇ ਇਸ ਵਿਚ ਬੰਕੀ ਆਈਐਚਐਚ ਦੇ ਨਾਲ-ਨਾਲ ਇਲੈਕਟਰਾਨਿਕ ਡੈਟੇਨੇਟਰ, ਇਕ ਬੈਟਰੀ, ਇਕ ਟਾਈਮਰ ਅਤੇ ਇਕ ਲੱਭੇ ਹੋਏ ਡੱਬਾ ਪਾਇਆ ਗਿਆ। ਐੱਸਐਸਪੀ

ਨੇ ਦੱਸਿਆ ਕਿ ਮੌਕੇ 'ਤੇ ਥੋਥ ਡਿਸਪੋਜ਼ਲ ਸਕ੍ਰਾਓਡ ਨੂੰ ਖੁਲਾਇਆ ਗਿਆ ਤੇ ਵਿਸ਼ੇਸ਼ ਸਮੱਗਰੀ ਨੂੰ ਮੌਕੇ 'ਤੇ ਹੀ ਸੁਰੱਖਿਅਤ ਢੰਗ ਨਾਲ ਨਸ਼ਟ ਕਰ ਦਿੱਤਾ ਗਿਆ, ਜਦੋਂ ਕਿ ਬਾਕੀ ਬਚੀਆਂ ਚੀਜ਼ਾਂ ਨੂੰ ਪੁਲਸ ਨੇ ਆਪਣੇ ਕਬਜ਼ੇ ਵਿਚ ਲੈ ਗਿਆ। ਇਸ ਸਬੰਧ ਵਿਚ ਐਫਐਮਐਲ ਥਾਣਾ ਰਾਮਦਾਸ ਵਿਚ ਦਰਜ ਕੀਤੀ ਗਈ ਹੈ।

ਦ ਨੋਬੇਲ ਸਕੂਲ ਨੇ 80ਵਾਂ ਸੁਤੰਤਰਤਾ ਦਿਵਸ ਮਨਾਇਆ

ਕਰਾਚਪੁਰ (ਹਰਮੇਸ਼ ਦੱਤਾ) : ਦ ਨੋਬੇਲ ਸਕੂਲ ਵਿੱਚ 80ਵਾਂ ਸੁਤੰਤਰਤਾ ਦਿਵਸ ਕੇਂਦਰ ਉਤਸ਼ਾਹ, ਦੇਸ਼ ਭਗਤੀ ਦੀ ਤਾਵਨਾ ਅਤੇ ਗ਼ਦਰ ਪ੍ਰਤੀ ਮਾਣ ਨਾਲ ਮਨਾਇਆ ਗਿਆ। ਇਸ ਮੌਕੇ ਵਿਦਿਆਰਥੀਆਂ ਅਤੇ ਅਧਿਆਪਕਾਂ ਨੇ ਇਕੱਠ ਹੋ ਕੇ ਭਾਰਤ ਦੀ ਆਜ਼ਾਦੀ ਨੂੰ ਯਾਦ



ਕੀਤਾ ਅਤੇ ਏਕਤਾ, ਹਿਮਤ ਅਤੇ ਦੇਸ਼ ਭਗਤੀ ਦੀ ਤਾਵਨਾ ਨੂੰ ਸਨਮਾਨ ਕੀਤਾ। ਪ੍ਰਸ਼ੰਸਕਾਂ ਦੀ ਸ਼ੁਰੂਆਤ ਭੰਡਾ ਲਹਿਰਾਉਣ ਦੀ ਰਸਮ ਨਾਲ ਹੋਈ, ਜਿਸ ਤੋਂ ਬਾਅਦ ਸਕੂਲ ਦਾ ਗੰਗਵਾਮੀ ਸਕੂਲ ਗੀਤ ਪੌਰ ਕੀਤਾ ਗਿਆ। ਭੰਡਾ ਲਹਿਰਾਉਣ ਦੀ ਰਸਮ ਕੀਤੀ ਗਈ। ਇਸ ਤੋਂ ਬਾਅਦ ਨੰਨੂ ਕਰਾਚਾਰ ਵੱਲੋਂ ਦੇਸ਼ ਭਗਤੀ ਤਰਜੁਮ ਪੇਸ਼ਕਾਰੀਆਂ ਦੀ ਲੜੀ ਪੇਸ਼ ਕੀਤੀ ਗਈ। ਤੀਜੀ ਸਮਾਤ ਦੇ ਵਿਦਿਆਰਥੀਆਂ ਨੇ ਫਿਰ ਵੀ ਇਕ ਹੋਰ ਹਿਦੁਆਨੀ 'ਤੇ ਮਨਮਾਨ ਪੇਸ਼ਕਾਰੀ ਦੇ ਕੇ ਸਰਕਾਰ 'ਤੇ ਮਾਨ ਮੰਨ ਲਿਆ, ਜਦਕਿ ਪੰਜਵੀਂ ਸਮਾਤ ਦੇ ਵਿਦਿਆਰਥੀਆਂ ਨੇ

ਓ ਦੇਸ਼ ਮੇਰੇ ਕੱਪੜੇ ਸੇ ਮਿਲਤੇ ਪੇਸ਼ ਕੀਤਾ। ਅਨੰਦੀ ਸਮਾਤ ਦੇ ਵਿਦਿਆਰਥੀਆਂ ਨੇ ਭਾਰਤ ਦੀ ਵਿਲੱਖਣ ਵਿਰਿਨਤਾ ਅਤੇ ਖੁਸ਼ੀਆਂ ਨੂੰ ਸ਼ਾਨਦਾਰ ਢੰਗ ਨਾਲ ਪੇਸ਼ ਕੀਤਾ। ਸੰਤਰੀ ਸਮਾਤ ਦੇ ਵਿਦਿਆਰਥੀ ਪਰਵੇਸ਼ ਨੇ ਭੌਰੀ ਪੁੱਤ 'ਤੇ ਵਿਸ਼ੇਸ਼ ਇਕਲ ਪੇਸ਼ਕਾਰੀ ਦਿੱਤੀ। ਦੇਸ਼

ਭਗਤੀ ਦਾ ਜਜ਼ਬਾ ਉਸ ਸਮੇਂ ਹੋਰ ਵੀ ਪੰਜਾਬ ਪੇਸ਼ ਕੀਤਾ ਜਦੋਂ ਭੌਰੀ ਸਮਾਤ ਦੇ ਵਿਦਿਆਰਥੀਆਂ ਨੇ ਮੇਰਾ ਦੇਸ਼ ਹੋਵੇ ਪੰਜਾਬ ਪੇਸ਼ ਕੀਤਾ ਅਤੇ ਪੰਜਵੀਂ ਸਮਾਤ ਦੀਆਂ ਵਿਦਿਆਰਥੀਆਂ ਨੇ ਤਿਰੰਗਾ ਦੀ ਪੇਸ਼ਕਾਰੀ ਰਾਹੀਂ ਗ਼ਦਰੀ ਭੰਡੇ ਦੇ ਤਿੰਨ ਰੰਗਾਂ ਦੀ ਖੁਸ਼ਬੂਤੀ ਅਤੇ ਮਾਣ ਨੂੰ ਜ਼ੋਰੀਤ ਕਰ ਦਿੱਤਾ। ਇਸ ਮੌਕੇ ਵਿਦਿਆਰਥੀ ਪਰਵੇਸ਼ ਨੂੰ ਸੀ. ਐਲ. ਕੋਫ਼ਤ, ਮੈਨੇਜਿੰਗ ਡਾਇਰੈਕਟਰ ਇੰਜੀ. ਕੁਮਾਰ ਸ਼ਿਵ ਕੋਫ਼ਤ, ਡਾਇਰੈਕਟਰ ਸੰਗਮ ਸ਼ਰਮਾ ਅਤੇ ਪ੍ਰਿੰਸੀਪਲ ਗਵਿੰਦਰ ਕੌਰ ਨੇ ਆਗੇਮਨ ਪ੍ਰਦਾਨ ਕੀਤਾ। ਤੀਜੀ ਸਮਾਤ ਦੇ ਵਿਦਿਆਰਥੀਆਂ ਨੇ ਫਿਰ ਵੀ ਇਕ ਹੋਰ ਹਿਦੁਆਨੀ 'ਤੇ ਮਨਮਾਨ ਪੇਸ਼ਕਾਰੀ ਦੇ ਕੇ ਸਰਕਾਰ 'ਤੇ ਮਾਨ ਮੰਨ ਲਿਆ, ਜਦਕਿ ਪੰਜਵੀਂ ਸਮਾਤ ਦੇ ਵਿਦਿਆਰਥੀਆਂ ਨੇ


ਮਾਤਾ ਚਿਤ੍ਰਪੁਨੀ ਲੰਗਰ ਕਮੇਟੀ ਨੇ ਸ਼ੋਭਾ ਯਾਤਰਾ ਕੱਢੀ



ਕਰਾਚਪੁਰ (ਹਰਮੇਸ਼ ਦੱਤਾ) : ਮਾਤਾ ਚਿਤ੍ਰਪੁਨੀ ਲੰਗਰ ਕਮੇਟੀ ਵਿਦਿਆਲਪ ਮੁਕਾਰ ਵੱਲੋਂ ਸਾਵਨ ਮਹੀਨੇ ਦੀ ਅਸ਼ਟਮੀ ਤੇ ਹਰ ਸਾਲ ਵਿਸ਼ਾਲ ਸਲਾਨਾ ਲੰਗਰ ਹਿਮਾਚਲ ਪ੍ਰਦੇਸ਼ ਵਿਖੇ ਲਗਾਇਆ ਜਾਂਦਾ ਹੈ। ਹਰ ਸਾਲ ਦੀ ਤਰ੍ਹਾਂ ਇਸ ਵਾਰ ਵੀ 32 ਵਾ ਸਾਲਾਨਾ ਲੰਗਰ 17,18,19,20 ਅਗਸਤ ਤੇ ਲੰਗਰ ਨਜਦੀਕ ਥੋਥੇ ਪਿਕਨਿਕ ਸਪੋਟ ਸੇਨ ਹਵੇਲੀ ਦੇ ਨਾਲ ਤੇ ਪਿੰਡਾ ਵਾਲੇ ਢਾਢੇ ਕੋਲ ਲਗਾਇਆ ਜਾਵੇਗਾ। ਇਸ ਸਬੰਧ ਵਿੱਚ ਪਿੰਡ ਵਿਦਿਆਲਪ ਵਿਖੇ ਜ਼ਿਲ੍ਹਾ ਜਲੰਧਰ ਵਿਖੇ ਵਿਸ਼ਾਲ ਸ਼ੋਭਾ ਯਾਤਰਾ ਕੱਢੀ ਗਈ ਜੋ ਕਿ ਬਾਜ਼ਾਰ ਵਾਲੇ ਸਿਥਾਲੇ ਮੋਰਟ ਅਤੇ ਹੋਰ ਤੇ ਪਿੰਡਾ ਵਾਲੇ ਢਾਢੇ ਦੀ ਪਹਿਰਕਮਾ ਕਰਨ ਤੋਂ ਬਾਅਦ ਸ਼ੁਰੂ ਮੰਦਰ ਵਿਖੇ ਸ਼ਾਮਪਤ ਹੋਈ ਸ਼ਰਧਾਲੂਆਂ ਨੇ ਫੁੱਲਾਂ ਦੀ ਵਰਖਾ ਨਾਲ ਮਹਾਮਾਈ ਦੀ ਜੋਤ ਦਾ ਸਵਾਗਤ ਕੀਤਾ ਅਤੇ ਨਤਮਸਤਕ ਹੋ ਕੇ ਮਹਾਮਾਈ ਜੀ ਦਾ ਅਸ਼ੀਰਵਾਦ ਪ੍ਰਾਪਤ ਕੀਤਾ। ਇਸ ਮੌਕੇ ਦਰਸਨਾ ਹੀ ਸਥਾਨਾ ਤੇ ਵੱਧ ਵੱਧ ਪ੍ਰਕਾਰ ਦੇ ਲੰਗਰ ਲਗਾਏ ਹੋਏ ਸਨ। ਇਸ ਮੌਕੇ ਲੰਗਰ ਕਮੇਟੀ ਦੇ ਪ੍ਰਬੰਧਕ ਸ਼ਰਧਾਲੂ ਅਤੇ ਸੇਵਾਦਾਰ ਹਾਜ਼ਰ ਸਨ।

ਜ਼ੋਨ-16 ਦੀਆਂ ਜ਼ੋਨਲ ਸਕੂਲ ਖੇਡਾਂ ਦਾ ਸ਼ਾਨਦਾਰ ਆਗਾਜ਼, 300 ਤੋਂ ਵੱਧ ਖਿਡਾਰੀਆਂ ਨੇ ਲਿਆ ਹਿੱਸਾ

ਬਾਕੋਟ (ਗਿਆਨ ਸੋਧਾਧੀ) : ਜਲੰਧਰ ਜ਼ੋਨ-16 ਦੀਆਂ ਜ਼ੋਨਲ ਸਕੂਲ ਖੇਡਾਂ 2026-27 ਦਾ ਆਯੋਜਨ ਸ਼ੀਵਪਾਲ ਖੇਡ ਟੈਰੇਸ਼ੀਅਰ ਵਿਖੇ ਕੀਤਾ ਗਿਆ। ਇਹ ਖੇਡਾਂ ਵਿੱਚ ਲੱਗਭੱਗ 300 ਤੋਂ ਵੱਧ ਲੜਕੇ ਅਤੇ ਲੜਕੀਆਂ ਨੇ ਉਤਸ਼ਾਹ ਨਾਲ ਭਾਗ ਲਿਆ। ਖੇਡਾਂ ਦਾ ਉਦਘਾਟਨ ਮੌਜੂਦ ਪਾਰਲੀਮੈਂਟ, ਵਾਤਾਵਰਨ ਪ੍ਰੇਮੀ ਅਤੇ ਪਦਮ ਸ਼੍ਰੀ ਸੰਤ ਬਲਬੀਰ ਸਿੰਘ ਸ਼ੀਵਪਾਲ ਵੱਲੋਂ ਕੀਤਾ ਗਿਆ। ਉਨ੍ਹਾਂ ਨੇ ਵਿਦਿਆਰਥੀਆਂ ਨੂੰ ਖੇਡਾਂ ਵਿੱਚ ਵੱਧ ਤੋਂ ਵੱਧ ਭਾਗ ਲੈਣ ਲਈ ਪ੍ਰੇਰਿਤ ਕਰਦਿਆਂ ਕਿਹਾ ਕਿ ਖੇਡਾਂ ਨਿਸ਼ਚਾਨਾਂ ਦੇ ਸ਼ਹੀਦ ਅਤੇ ਮਾਨਸਿਕ ਵਿਕਾਸ ਦੇ ਨਾਲ-ਨਾਲ ਉਨ੍ਹਾਂ ਵਿੱਚ ਆਤਮਸ਼ਾਨ ਅਤੇ ਟੀਮ ਭਾਵਨਾ ਪੈਦਾ ਕਰਦੀਆਂ ਹਨ। ਇਸ ਮੌਕੇ ਮੁਕਾਬਲਿਆਂ ਦੇ ਨਾਲ-ਨਾਲ ਵਿਦਿਆਰਥੀਆਂ ਵੱਲੋਂ ਸ਼ਾਨਦਾਰ ਸੰਗੀਤਾਚਾਰ ਪ੍ਰਦਰਸ਼ਨ ਵੀ ਪੇਸ਼ ਕੀਤਾ ਗਿਆ। ਬੱਚਿਆਂ ਨੇ ਪੰਜਾਬੀ ਸੰਗੀਤਕਾਰ ਨਾਲ ਸਬੰਧਤ ਵੱਖ-ਵੱਖ ਪੇਸ਼ਕਾਰੀਆਂ ਰਾਹੀਂ ਆਪਣੀ ਪ੍ਰਤਿਭਾ ਦਾ ਪ੍ਰਦਰਸ਼ਨ ਕੀਤਾ। ਜ਼ੋਨਲ ਖੇਡਾਂ ਵਿੱਚ ਸਰਕਾਰੀ ਅਤੇ ਪ੍ਰਾਈਵੇਟ ਸਕੂਲਾਂ ਦੇ ਵਿਦਿਆਰਥੀਆਂ ਦੀ ਵੱਡੀ ਗਿਣਤੀ ਨੇ ਇਲਾਕੇ ਵਿੱਚ ਖੇਡਾਂ ਪ੍ਰਤੀ ਵੱਧ ਹੋਰ ਉਤਸ਼ਾਹ ਨੂੰ ਦਰਸਾਇਆ। ਪ੍ਰਬੰਧਕਾਂ ਅਤੇ ਅਧਿਆਪਕਾਂ ਨੇ ਖਿਡਾਰੀਆਂ ਨੂੰ ਖੇਡ ਭਾਵਨਾ ਨਾਲ ਮੁਕਾਬਲਿਆਂ ਵਿੱਚ ਭਾਗ ਲੈਣ ਅਤੇ ਆਪਣੇ ਸਕੂਲ ਤੇ ਇਲਾਕੇ ਦਾ ਨਾਮ ਗੌਰ ਕਰਨ ਲਈ ਪ੍ਰੇਰਿਤ ਕੀਤਾ।



ਅਥਲੈਟਿਕਸ ਮੁਕਾਬਲੇ ਕਰਵਾਏ

ਸੁਲਤਾਨਪੁਰ ਲੋਧੀ, (ਭਲੀ) : ਪੰਜਾਬ ਸਕੂਲ ਖੇਡਾਂ ਦੇ ਬਣਾਧ ਸੁਲਤਾਨਪੁਰ ਲੋਧੀ -1 ਦੇ ਅਥਲੈਟਿਕਸ ਮੁਕਾਬਲੇ ਸਰਕਾਰੀ ਸੀਨੀਅਰ ਮੈਡੀਕਲ ਸਕੂਲ ਤਲਵੰਡੀ ਚੌਧਰੀਆਂ ਵਿਖੇ ਕਰਵਾਏ ਗਏ। ਜਿਸ ਵਿੱਚ ਸ਼ਿਕਾਰ ਕਰਦਿਆਂ ਵਾਜਕਨ ਇੰਟਰਨੈਸ਼ਨਲ ਸਕੂਲ ਦੇ ਖਿਡਾਰੀਆਂ ਨੇ ਬਹੁਤ ਵਧੀਆ ਪ੍ਰਦਰਸ਼ਨ ਕੀਤਾ। ਪ੍ਰਭੂਨਾ ਸਿੰਘ ਨੇ 100 ਅਤੇ 200 ਮੀਟਰ ਦੌੜ 'ਚ ਪ੍ਰਤਿਭਾ ਸਥਾਨ ਪ੍ਰਾਪਤ ਕੀਤਾ। ਪੁਰਜੋਤ ਕੌਰ ਨੇ 200 ਮੀਟਰ ਦੌੜ



ਚੋਂ ਪਹਿਲਾਂ ਸਥਾਨ ਪ੍ਰਾਪਤ ਕੀਤਾ। ਹਮੀਦ ਸਿੰਘ ਨੇ ਅੰਡਰ 19 ਵਰਗ ਵਿੱਚੋਂ 100 ਮੀਟਰ ਰੇਸ ਵਿੱਚ ਤੀਜਾ ਅਤੇ 200 ਮੀਟਰ ਰੇਸ ਵਿੱਚ ਦੂਜਾ ਸਥਾਨ ਹਾਸਲ ਕੀਤਾ। ਅੰਡਰ 14 ਵਰਗ ਵਿੱਚੋਂ ਸੁਖਮਨਪ੍ਰੀਤ ਸਿੰਘ ਨੇ 200 ਮੀਟਰ ਰੇਸ ਵਿੱਚ ਪਹਿਲਾਂ ਸਥਾਨ ਹਾਸਲ ਕੀਤਾ ਅਤੇ ਗੁਰਨੁਕਪੀਤ ਕੌਰ ਨੇ 600 ਮੀਟਰ ਰੇਸ ਜਿੱਤ ਕੇ ਗੋਲਡ ਮੈਡਲ ਹਾਸਲ ਕੀਤਾ। ਸਕੂਲ ਦੇ ਚੇਅਰਮੈਨ ਕਰਨਲ ਅਜੀਤ ਸਿੰਘ ਇੱਥੋਂ ਤੇ ਮੈਨੇਜਿੰਗ ਡਾਇਰੈਕਟਰ ਮੋਹਨ ਨਦਰਪਤ ਕੌਰ ਇੱਥੋਂ ਨੇ ਸਕੂਲ ਦੇ ਖਿਡਾਰੀਆਂ ਨੂੰ ਜਿੱਤਣ 'ਤੇ ਵਧਾਈ ਦਿੱਤੀ ਅਤੇ ਕਰੀਬ ਵਿੱਚ ਹੋਰ ਮਿਲਨ ਕਰਨ ਲਈ ਪ੍ਰੇਰਿਤ ਕੀਤਾ। ਵਾਜਕਨ ਇੰਟਰਨੈਸ਼ਨਲ ਸਕੂਲ ਦੇ ਚੇਅਰਮੈਨ ਕਰਨਲ ਅਜੀਤ ਸਿੰਘ ਇੱਥੋਂ ਅਤੇ ਮੈਨੇਜਿੰਗ ਡਾਇਰੈਕਟਰ ਨਦਰਪਤ ਕੌਰ ਇੱਥੋਂ ਦੇ ਇਸ ਜਿੱਤ ਦਾ ਸ਼ਿਰਾ ਅਧਿਆਪਕਾਂ ਦੇ ਵਿਦਿਆਰਥੀਆਂ ਦੀ ਅਣਖੀ ਮਿਲਨ ਨੂੰ ਦਿੱਤਾ।

ਬੀ ਏ ਬੀ ਐੱਫ ਤੀਜੇ ਸੈਮੈਸਟਰ ਦਾ ਨਤੀਜਾ ਸ਼ਾਨਦਾਰ ਰਿਹਾ

ਗੁਰਮੁਖ (ਕੁਲਾ ਸਿੰਘ ਗੋਰਾਖਪੁਰ) : ਬੰਬਰ ਅਕਾਲੀ ਮੋਰਚੀਅਨ ਖਾਲਸਾ ਕਾਲਜ ਗੁਰਮੁਖ ਵਿਖੇ ਚੱਲ ਰਹੇ ਚਾਰ ਸਾਲਾ ਇੰਟਰਮੀਡੀਏਟ ਕੋਰਸ ਬੀ ਏ ਬੀ ਐੱਫ ਤੇ ਤੀਜੇ ਸੈਮੈਸਟਰ ਦਾ ਨਤੀਜਾ ਸ਼ਾਨਦਾਰ ਰਿਹਾ ਹੈ। ਪ੍ਰਿੰਸੀਪਲ ਡਾ. ਅਨਦੀਪ ਹੀਰਾ ਨੇ ਦੱਸਿਆ ਕਿ ਪੰਜਾਬ 'ਵਰਸਿਟੀ' ਵੱਲੋਂ ਐਲਾਨ ਕੀਤੇ ਗਏ ਬੀ ਏ ਬੀ ਐੱਫ ਤੀਜੇ ਸੈਮੈਸਟਰ ਦੇ ਨਤੀਜੇ ਵਿਦਿਆਰਥੀਆਂ ਨੇ 85.6 ਫੀਸਦੀ ਅੰਕ ਲੈ ਕੇ ਕਲਾਸ ਵਿੱਚ ਪਹਿਲਾਂ ਸਥਾਨ, ਬਲਬੀਨ ਕੌਰ ਨੇ 85 ਫੀਸਦੀ ਅੰਕ ਲੈ ਕੇ ਦੂਜਾ ਤੇ ਹਰਮਨ ਨੇ 84.4 ਫੀਸਦੀ ਅੰਕ ਲੈ ਕੇ ਤੀਜਾ ਸਥਾਨ ਹਾਸਲ ਕੀਤਾ ਹੈ। ਪ੍ਰਿੰਸੀਪਲ ਡਾ. ਅਨਦੀਪ ਹੀਰਾ ਨੇ ਸ਼ਾਨਦਾਰ ਨਤੀਜੇ ਲਈ ਵਿਦਿਆਰਥੀਆਂ, ਉਨ੍ਹਾਂ ਦੇ ਮਾਪਿਆਂ ਤੇ ਸਟਾਫ ਨੂੰ ਵਧਾਈ ਦਿੱਤੀ ਤੇ ਵਿਦਿਆਰਥੀਆਂ ਨੂੰ ਕਰੀਬ ਵਿਚ ਹੋਰ ਵੀ ਚੰਗੇ ਅੰਕ ਲੈ ਕੇ ਅੱਗੇ ਵਧਣ ਲਈ ਪ੍ਰੇਰਿਤ ਕੀਤਾ।

80ਵਾਂ ਆਜ਼ਾਦੀ ਦਿਵਸ ਦੇਸ਼ ਭਗਤੀ ਭਾਵਨਾ ਤੇ ਉਤਸ਼ਾਹ ਨਾਲ ਮਨਾਇਆ



ਮੋਹਾਲੀ (ਗੁਰਜੀਤ ਬਿੱਲਾ